Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

ELN Connector

July 21, 2010 8:53 am | Product Releases | Comments

Labtronics Inc., a world leader in laboratory automation has released a Connector for Nexxis ELN that allows the Electronic Laboratory Notebook to connect to any LIMS.


Gene Expression Assay

July 21, 2010 8:41 am | Drug Discovery & Development | Product Releases | Comments

Affymetrix, Inc. announced the launch of QuantiGene ViewRNA Assay formats, which enable a new era of “in situ multiplex gene expression analysis” by allowing drug screening of native cells and advancing the pace of biomarker disease research and stem cell studies.


Ricera Launches Foresight Service

July 21, 2010 8:35 am | News | Comments

Ricerca Biosciences, LLC, a uniquely integrated preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, has announced its innovative similarity analysis service, Foresight.


Lilly Buys Alnara for $180M

July 21, 2010 8:30 am | News | Comments

Eli Lilly and Company announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of metabolic diseases.


PROLOR Begins New Trial of Long-Lasting HGH

July 21, 2010 8:26 am | News | Comments

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, announced initiation of a Phase 2 clinical trial of hGH-CTP, the company’s proprietary biobetter version of human growth hormone (hGH).


Aganocide Effective Against Impetigo

July 21, 2010 8:00 am | News | Comments

NovaBay Pharmaceuticals, Inc. announced results from a Phase 2a trial that show its lead product candidate is safe and efficacious against the highly contagious skin infection impetigo, including those infections caused by drug-resistant MRSA.


Mechanical Stimulation Triggers Bone Growth

July 21, 2010 7:50 am | News | Comments

A long-standing question in bone biology has been answered: It is the spindly extensions of bone cells that sense mechanical stimulation and signal the release of bone-growth factors.


Antibiotic-Infection Tag Team Promising Against Malaria

July 21, 2010 7:47 am | News | Comments

If mice are administered an antibiotic for three days and are simultaneously infected with malaria, no parasites appear in the blood and life-threatening disease is averted. In addition, the animals treated in this manner also develop robust, long-term immunity against subsequent infections.


Stem Cells Mitigate Aftermath of Heart Attacks

July 21, 2010 7:31 am | News | Comments

Implanting tiny plastic scaffolds seeded with genetically engineered stem cells reduced organ damage and led to better cardiac function after a heart attack, according to a recent animal study.


Deuterium Swap Results In Better Fluorescent Probes

July 21, 2010 7:17 am | News | Comments

By swapping out one specific hydrogen atom for an isotope twice as heavy, researchers have increased the shelf life and detection ability of fluorescent probes that are essential to studying a variety of inflammatory diseases, including cancer and atherosclerosis.


Important Prostate Cancer Pathway Blocked

July 21, 2010 7:09 am | News | Comments

Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow prostate tumors to produce androgens could be the key in halting the cancer's growth.


Gilead Q2 Revenues Jump 17% From Previous Year

July 21, 2010 6:53 am | News | Comments

Gilead Sciences, Inc. announced that its total revenues for the second quarter of 2010 were $1.93 billion, up 17% compared to total revenues of $1.65 billion for the second quarter of 2009.


Panel Pans Avastin Breast Cancer Approval

July 21, 2010 6:29 am | by Matthew Perrone | News | Comments

A panel of cancer experts said that the government should remove its endorsement of Roche's drug Avastin for breast cancer, after follow-up studies failed to show benefits for patients.


GSK Legal Woes Take Toll on Profits

July 21, 2010 6:22 am | by Robert Barr | News | Comments

GlaxoSmithKline, the world's second-largest pharmaceutical company by revenue, reported a loss of $464 million for the second quarter as the company absorbed a hit of $2.4 billion for settling lawsuits.


Abbott Profits Steady in Second Quarter

July 21, 2010 6:19 am | News | Comments

Abbott Laboratories said its net income was unchanged in the second quarter as greater expenses canceled out higher revenue from Abbott's drugs and medical devices and from companies it recently acquired.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.